Acting On Ester Bond (3.1) Patents (Class 435/196)
-
Publication number: 20140186920Abstract: A method of increasing production of fatty acids comprising introducing into a host and expressing therein an acyl-acyl carrier protein (ACP) thioesterase (TE) from Bryantella formatexigens or a mutant thereof; a method of making a mutant B. formatexigens acyl-ACP TE; a method of making a chimeric Cuphea viscosissima acyl-ACP TE; a nucleic acid molecule comprising a nucleotide sequence encoding a mutant acyl-ACP TE or a chimeric Cuphea viscosissima acyl-ACP TE; a host comprising the nucleic acid molecule; a mutant acyl-ACP TE or chimeric Cuphea viscosissima acyl-ACP TE; a method of altering the specificity of a plant acyl-ACP TE for at least one of its substrates comprising introducing into the plant acyl-ACP TE a substrate specificity-altering mutation; and a method of altering the level of activity of a plant acyl-ACP TE.Type: ApplicationFiled: December 26, 2013Publication date: July 3, 2014Applicant: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Basil J. Nikolau, Marna Yandeau-Nelson, Fuyuan Jing
-
Publication number: 20140186919Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.Type: ApplicationFiled: December 12, 2013Publication date: July 3, 2014Inventors: Feng ZHANG, Fei RAN, Ophir SHALEM
-
Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof
Patent number: 8765437Abstract: This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome).Type: GrantFiled: July 22, 2011Date of Patent: July 1, 2014Assignee: Biomarin Pharmaceutical Inc.Inventors: Vish Koppaka, Michel Claude Vellard, Augustus O. Okhamafe, Kidisti Araya -
Patent number: 8765431Abstract: Disclosed herein are methods of preparing alkenes from beta-hydroxy or beta-sulfate carboxylic acid or carboxylic acid derivatives using thioesterase and optionally a sulfotransferase.Type: GrantFiled: July 23, 2010Date of Patent: July 1, 2014Assignee: The Regents of the University of MichiganInventors: David H. Sherman, Janet L. Smith, Liangcai Gu, Jennifer Gehret
-
Publication number: 20140178350Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).Type: ApplicationFiled: July 31, 2013Publication date: June 26, 2014Applicant: biOasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20140178933Abstract: An expression vector which is capable of overexpressing a protein of interest in a host cell, a host cell comprising the expression vector, and a method of producing a protein of interest are provided.Type: ApplicationFiled: April 30, 2012Publication date: June 26, 2014Applicants: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY, Samsung Electronics Co., Ltd.Inventors: Hyun Min Koo, Byung Jo Yu, Ki Sung Lee, Jae Chan Park, Dae Hyuk Kweon, Sung Minm Park
-
Patent number: 8759040Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: June 24, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8759041Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: June 24, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Publication number: 20140170130Abstract: A novel peptide sequence that is a modified derivative of a neuron-specific tyrosine phosphatase is shown and described. Specifically, the novel peptide sequence is a modified derivative of striatal-enriched tyrosine phosphatase (STEP). The peptide sequence has been modified so as to be able to ameliorate and treat brain injury resulting from excessive glutamate release and/or oxidative stress. Examples of the types of brain injury which the presently disclosed peptide sequence is useful for treating includes acute brain injury resulting from stroke or traumatic brain injury and chronic disorders such as Huntington's chorea and schizophrenia. Furthermore, the presently described peptide sequence may further be useful in the treatment and amelioration of disorders associated with fear memory such as post-traumatic stress disorder.Type: ApplicationFiled: September 15, 2011Publication date: June 19, 2014Applicant: STC.UNMInventor: Surojit Paul
-
Patent number: 8753860Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: June 17, 2014Assignee: Novozymes A/SInventors: Marc D. Morant, Paul Harris
-
Patent number: 8753847Abstract: Compositions and methods are provided for selection and enrichment of a target gene from a library of polynucleotide sequences such as might be formed from a genome or by random mutagenesis of a genetic sequence. The selection and enrichment occurs in aqueous droplets formed in an emulsion that compartmentalize individual polynucleotides from the library or a plurality of polynucleotides that may include polynucleotides not derived from the library, transcription and translation reagents and optionally additional chemical and enzyme reagents. The selection and enrichment method utilizes a polynucleotide adaptor which when ligated to the polynucleotide fragment enables amplification to occur in the presence of an adaptor specific primer.Type: GrantFiled: August 13, 2013Date of Patent: June 17, 2014Assignee: New England Biolabs, Inc.Inventors: Yu Zheng, Richard J. Roberts
-
Patent number: 8753858Abstract: The present disclosure relates to stabilizers for alkaline phosphatase or conjugates thereof, a process for preparing a stabilizer, and a method for stabilizing alkaline phosphatase or conjugates thereof with a stabilizer. The present disclosure also relates to a reagent of alkaline phosphatase or conjugates thereof as well as to a process for preparing the same. In another aspect, the present disclosure relates to a kit comprising the stabilizers disclosed herein and alkaline phosphatase or conjugates thereof. The stabilizer disclosed herein can stabilize alkaline phosphatase or conjugates thereof for a prolonged period of time, extending their shelf-life.Type: GrantFiled: December 29, 2010Date of Patent: June 17, 2014Assignee: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.Inventors: Chungen Qian, Yuping Zhang
-
Patent number: 8748100Abstract: Disclosed herein are methods and kits for selectively amplifying, detecting or quantifying a DNA fragment with a specific end sequence, especially generated following restriction enzyme digestion. This method can be used, for example, to detect a hypomethylated DNA fragment. This methods and kits are especially useful in detecting or quantifying a hypomethylated fetal DNA fragment in a maternal plasma sample containing a corresponding hypermethylated maternal DNA fragment.Type: GrantFiled: August 30, 2007Date of Patent: June 10, 2014Assignee: The Chinese University of Hong KongInventors: Yuk Ming Dennis Lo, Yu Kwan Tong, Wai Kwun Rossa Chiu, Chunming Ding
-
Publication number: 20140154778Abstract: Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer.Type: ApplicationFiled: December 20, 2013Publication date: June 5, 2014Applicant: NEW ENGLAND BIOLABS, INC.Inventors: Zhenyu Zhu, Aine Quimby, Shengxi Guan, Dapeng Sun, Yishu Huang, Xuhui Lai, Siu-hong Chan, Xianghui Li, Shuang-Yong Xu, Chunhua Zhang
-
Publication number: 20140154779Abstract: Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer.Type: ApplicationFiled: December 20, 2013Publication date: June 5, 2014Applicant: NEW ENGLAND BIOLABS, INC.Inventors: Zhenyu Zhu, Aine Quimby, Shengxi Guan, Dapeng Sun, Yishu Huang, Xuhui Lai, Siu-hong Chan, Xianghui Li, Shuang-Yong Xu, Chunhua Zhang
-
Patent number: 8735124Abstract: An isolated polypeptide comprising the amino acid sequence of serum paraoxonase (PON1) having catalytic efficiency of kcat/KM?106-5·107 M?1min?1 for a G-type organophosphate.Type: GrantFiled: March 15, 2012Date of Patent: May 27, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Dan S. Tawfik, Rinkoo Devi Gupta, Moshe Goldsmith, Yaacov Ashani
-
Patent number: 8735125Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: GrantFiled: October 22, 2012Date of Patent: May 27, 2014Assignee: E. I. du Pont de Nemours and CompanyInventors: Robert Dicosimo, Mark Scott Payne, John Edward Gavagan
-
Patent number: 8735123Abstract: The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5.Type: GrantFiled: April 16, 2013Date of Patent: May 27, 2014Assignee: DuPont Nutrition BioSciences ApSInventors: Mai Faurschou Isaksen, Rikke Hoegh Lorentsen, Peter Plumstead, Luis Fernando Romero Millan, Susan Madrid, Cherry Lin, Michael Ward, Masoud Rajabi Zargahi
-
Publication number: 20140143908Abstract: The present invention relates generally to the field of molecular biology and regards various polynucleotides, polypeptides and methods that may be employed to enhance yield in transgenic plants. Specifically the transgenic plants may exhibit any one of the traits consisting of increased yield, increased tolerance to abiotic stress, increased cell growth and increased nutrient use efficiency.Type: ApplicationFiled: July 16, 2012Publication date: May 22, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Shib Basu, Jonathan Cohn, Michael L. Nuccio
-
Patent number: 8722866Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.Type: GrantFiled: January 18, 2007Date of Patent: May 13, 2014Assignee: The United States of America, as Represented by the Department of Veterans AffairsInventor: Matthew A. Movsesian
-
Publication number: 20140127752Abstract: A composition and method of cleaving a target DNA and isolating a DNA sequence of interest, directed by a targeting oligonucleotide (“ON”) including a DNA binding agent (stable or unstable), is disclosed. The targeting ON binds to the target DNA before or during DNA cleavage. After cleavage, the isolation of the DNA fragment of interest is facilitated by the affinity tag on the targeting ON or an affinity tag attached using either ligation or polymerase extension method.Type: ApplicationFiled: November 7, 2013Publication date: May 8, 2014Inventors: Zhaohui Zhou, Yue Xu, Qun Shan
-
Publication number: 20140127307Abstract: The present invention relates to a small particle size composition comprising pancreatin containing digestive enzymes for use in patients in need, including pediatric, geriatric, and adult patients, particularly those patients with dysphagia or wherein enteral administration using such composition would be suitable. In addition, the invention is directed to the composition as particles, such as micropellets or microgranules having a high potency, high useable yield and at least 10%-90% of 400-800 ?m. Furthermore, the composition optionally has an improved enteric coating and concomitant improved stability and enzyme activity compared to conventional prepared enterically coated pancreatic enzyme particles.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Applicant: APTALIS PHARMA LIMITEDInventors: Gopi M. VENKATESH, Craig Kramer, Flavio Fabiani, Luigi Mapelli, Giovanni Ortenzi, Massimo Latino
-
Publication number: 20140127190Abstract: Described herein are peptides from secretory phospholipase A2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jordan Marshall Sand, Mark Eric Cook, Daniel Elmer Butz
-
Patent number: 8716022Abstract: The invention provides methods of modifying the level of expression or functional activity of factors such as enzymes or other catalytic proteins or structural proteins, alone or in concert, to modify the frequency of meiotic homologous recombination involving the exchange of genetic information between non-sister chromatids from homologous maternal and paternal chromosomes. The steps at which modulation may occur include: homologous chromosome pairing, double-strand break formation; resection; strand invasion; branch migration; and resolution. Methods of plant and animal breeding are also provided that utilize the modulation of meiotic homologous recombination.Type: GrantFiled: September 12, 2001Date of Patent: May 6, 2014Assignee: Her Majesty the Queen in Right of Canada, as Represented by the Minister of Agriculture and Agri-FoodInventors: Kevin L. Rozwadowski, Derek J. Lydiate
-
Patent number: 8709773Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: May 6, 2010Date of Patent: April 29, 2014Assignee: Novozymes A/SInventors: Steffen Danielsen, Lars Kobberoee Skov, Ricardo Leite, Vincent Laizé, M Leonor Cancela Da Fonseca
-
Patent number: 8710012Abstract: A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.Type: GrantFiled: February 19, 2010Date of Patent: April 29, 2014Assignee: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20140112896Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for the provision of proteins lacking or deficient in subjects with a lysosomal storage disease and treatment and/or prevention of lysosomal storage diseases.Type: ApplicationFiled: July 11, 2013Publication date: April 24, 2014Inventor: Edward J. Rebar
-
Publication number: 20140112904Abstract: A method for enhancing the cleavage activity of an I-CreI derived meganuclease, comprising the site-specific mutation of at least one amino acid residue which is selected in the group consisting of: the glycine at position 19, the phenylalanine at position 54, the phenylalanine at position 87, the serine at position 79, the valine at position 105 and the isoleucine at position 132 of I-CreI, and its application for the manufacturing of meganuclease cleaving a DNA target of interest, for use in genome therapy (treatment of genetic diseases) and genome engineering (making of transgenic animals, transgenic plants and recombinant cell lines).Type: ApplicationFiled: June 6, 2008Publication date: April 24, 2014Applicant: CellectisInventors: Sylvestre Grizot, Agnes Gouble, Christophe Perez-Michaut
-
Patent number: 8703462Abstract: An enzyme preparation is described that includes a non-specific nuclease and a T7 Endo I mutant in a unit ratio of less than 1:200. This enzyme preparation may be used to generate double-stranded DNA fragments of a size suitable for DNA sequencing. The ends of the fragments can be readily modified as necessary to ligate adaptors or individual nucleotides to one strand of the double-stranded DNA fragments.Type: GrantFiled: February 3, 2010Date of Patent: April 22, 2014Assignee: New England Biolabs, Inc.Inventors: Pei-Chung Hsieh, Chudi Guan
-
Patent number: 8697063Abstract: The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella, and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: GrantFiled: December 16, 2011Date of Patent: April 15, 2014Assignee: Novozymes A/SInventors: Carsten Sjoeholm, Soeren Flensted Lassen, Lars Kobberoee Skov, Leonardo De Maria
-
Publication number: 20140099696Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: April 30, 2013Publication date: April 10, 2014Applicant: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang
-
Publication number: 20140093921Abstract: There is provided a recombinant bacterium comprising at least one overexpressed acyl-ACP thioesterase gene, and wherein at least one gene from the tricarboxylic acid cycle or glycolysis or both is inactivated. There is also provided a method for producing fatty acids, said method comprising culturing bacteria comprising at least one overexpressed acyl-ACP thioesterase gene in a growth medium in a container having walls; allowing said bacteria to secrete fatty acids; and collecting said fatty acids. Acid supplementation is also shown to increase productivity.Type: ApplicationFiled: March 18, 2011Publication date: April 3, 2014Applicant: WILLIAM MARSH RICE UNIVERSITYInventors: Ka-Yiu San, Mai Li, Xiujun Zhang
-
Publication number: 20140093938Abstract: The invention provides methods of removing nucleic acid contamination from reverse transcription reactions and hot-start PCR, wherein said hot-start PCR is a barrier hot-start PCR set up and/or involves a hot-start DNA polymerase, which methods comprise use of a DNase that is substantially irreversibly inactivated by heating at a temperature of about 50° C. for 5 minutes, and that is substantially specific for double stranded DNA. The invention further provides a DNase that is substantially irreversibly inactivated by heating at a temperature of about 50° C. for 5 minutes, and that is substantially specific for double stranded DNA, nucleic acids encoding said DNase and kits or compositions comprising said DNase or said nucleic acid.Type: ApplicationFiled: September 25, 2013Publication date: April 3, 2014Applicant: BIOTEC PHARMACON ASAInventors: Olav Lanes, Morten Elde, Dag Rune Gjellesvik
-
Publication number: 20140093878Abstract: Provided herein are mutant endonuclease V enzymes that are capable of nicking an inosine-containing DNA sequence. Nucleic acid assays and agents that employ such mutant endonuclease V enzymes to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of a target DNA are also described.Type: ApplicationFiled: March 15, 2013Publication date: April 3, 2014Applicant: GENERAL ELECTRIC COMPANYInventor: General Electric Company
-
Patent number: 8685663Abstract: A method for measuring cholesterol in low-density lipoprotein contained in a sample, which comprises reacting a sample with (i) a combination of cholesterol ester hydrolase and cholesterol oxidase or (ii) a combination of cholesterol ester hydrolase, an oxidized coenzyme and cholesterol dehydrogenase in the presence of: [a] a polyoxyethylene-polyoxyalkylene alkylaryl ether; [b] one or more surfactants selected from the group consisting of a polyoxyethylene-polyoxyalkylene copolymer, a polyoxyethylene alkenyl ether, a polyoxyethylene branched alkyl ether, and a polyoxyethylene-polyoxyalkylene branched alkyl ether; [c] one or more surfactants selected from the group consisting of a primary amine, a secondary amine, a tertiary amine, and a quaternary ammonium; and [d] a polyanion, and measuring a substance formed or consumed in the reaction.Type: GrantFiled: November 13, 2009Date of Patent: April 1, 2014Assignee: Kyowa Medex Co., Ltd.Inventors: Tomomi Murakami, Tomoko Aratake, Shingo Mishima, Hideyuki Kuwata
-
Publication number: 20140090116Abstract: Methods and compositions for gene disruption, gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a soybean cell, to generate a break in the FAD2 gene and then optionally integrating into the break a nucleic acid molecule of interest is disclosed.Type: ApplicationFiled: September 5, 2013Publication date: March 27, 2014Inventors: William Michael Ainley, Steven R. Webb, Pon Samuel, Dmitry Y. Guschin, Jeffrey C. Miller, Lei Zhang
-
Publication number: 20140090112Abstract: A method of gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a cell, to generate a break in the FAD2 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.Type: ApplicationFiled: September 5, 2013Publication date: March 27, 2014Inventors: Noel Cogan, John Forster, Matthew Hayden, Tim Sawbridge, German Spangenberg, Steven R. Webb, Manju Gupta, William Michael Ainley, Matthew J. Henry, Jeffrey C. Miller, Dmitry Y. Guschin
-
Patent number: 8673609Abstract: Provided herein are variants of Buttiauxella sp. phytases that may be used in industrial applications including methods for starch liquefaction, alcohol fermentations and for enhancing phosphate digestion in foods and animal feeds.Type: GrantFiled: April 17, 2009Date of Patent: March 18, 2014Assignee: Danisco US Inc.Inventors: Oliver Kensch, Klaus Schulze Pellengahr, Birgitta Leuthner, Jayarama K. Shetty, Michael Pepsin, Søren Dalsgaard, Mai Faurschou Isaksen
-
Publication number: 20140072548Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.Type: ApplicationFiled: August 2, 2013Publication date: March 13, 2014Applicant: Shire Pharmaceuticals Ireland LimitedInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Christer Moller, Pia Hyden
-
Patent number: 8663963Abstract: The present invention relates to isolated polypeptides having phytase activity and isolated polynucleotides encoding the polypeptides. The polypeptides are related to a phytase derived from Hafnia alvei, the amino acid sequence of which is shown in the appended sequence listing as SEQ ID NO: 10. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides, in particular within animal feed.Type: GrantFiled: February 23, 2011Date of Patent: March 4, 2014Assignee: Novozymes A/SInventors: Soeren Flensted Lassen, Carsten Sjoeholm, Lars Kobberoee Skov
-
Publication number: 20140056868Abstract: In some embodiments the present disclosure provides a composition for targeted alteration of a DNA sequence and methods of altering the targeted DNA sequence using the composition. In some embodiments such a composition comprises a MiniVector comprising a nucleic acid sequence template for homology-directed repair, alteration, or replacement of the targeted DNA sequence within a cell in vivo or in vitro, where the MiniVector lacks both a bacterial origin of replication and an antibiotic selection gene, and wherein the MiniVector has a size up to about 2,500 base pairs.Type: ApplicationFiled: May 30, 2013Publication date: February 27, 2014Applicants: University of Washington Center for Commercialization, Baylor College of MedicineInventors: Lynn E. Zechiedrich, Jonathan Fogg, Daniel James Catanese, JR., Erol Bakkalbasi, Nancy Maizel, Olivier Humbert
-
Patent number: 8658409Abstract: The present invention relates to isolated polypeptides having acetyl xylan esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: March 23, 2010Date of Patent: February 25, 2014Assignee: Novozymes A/SInventors: Johan Borjesson, Anders Viksoe-Nielsen, Peter Kamp Hansen
-
Publication number: 20140051128Abstract: The present invention relates to production of fermentable sugars from lignocellulosic material by enzymatic conversion. The fermentable sugars are useful e.g. in the production of bioethanol. Novel polypeptides having endoglucanase activity, polynucleotides encoding them and vectors and host cells containing the polynucleotides are disclosed. A method for treating cellulosic material with the novel endoglucanase as well as uses of the enzymes and enzyme preparations and a method of preparing them are described.Type: ApplicationFiled: May 24, 2013Publication date: February 20, 2014Applicant: ROAL OYInventors: Taija LEINONEN, Alexandra KOMANDER, Kim LANGFELDER, Jari VEHMAANPERÄ, Terhi PURANEN
-
Publication number: 20140051130Abstract: The present invention relates to enzyme compositions for high temperature saccharification of cellulosic material and to uses thereof.Type: ApplicationFiled: October 11, 2013Publication date: February 20, 2014Inventors: Brett McBrayer, Tarana Shaghasi, Elena Vlasenko
-
Patent number: 8653007Abstract: Compositions, methods and related uses are provided relating to cleaving modified DNA. For example, a set of DNA fragments obtainable by enzymatic cleavage of a large DNA is described where at least 50% are similarly sized and have a centrally positioned modified nucleotide. In addition, an enzyme preparation is provided that includes one or more enzymes that recognize a modified nucleotide in a DNA and cleave the DNA at a site that is at a non-random distance from the modified nucleotide. The one or more enzymes are further characterized by an N-terminal conserved domain with greater than 90% amino acid sequence homology to WXD(X)10YXGD. The related uses include creating a methylome, methods of purifying DNA fragments containing a modified nucleotide and diagnostic applications.Type: GrantFiled: April 6, 2012Date of Patent: February 18, 2014Assignee: New England Biolabs, Inc.Inventors: Yu Zheng, Richard J. Roberts
-
Patent number: 8652820Abstract: This invention relates to cloning and sequencing of thermotolerant phytase gene from Non-K12 Escherichia coli strain, ATCC 9637, phytase gene expression in Escherichia coli expression system, codon usage optimized and expression in Pichia pastoris, Pichia methanolica and Kluyeromyces lactis. The high level yield and thermotolerant enzyme was produced from fermentation of Pichia pastoris with optimized codon of phytase gene.Type: GrantFiled: November 14, 2008Date of Patent: February 18, 2014Assignee: Fujian Fuda Biotech Co. Ltd.Inventors: Xiuyun Ye, Renkuan Li, Weigang Jin, Caifang Chen
-
Publication number: 20140044835Abstract: The invention relates to a synthetic phytase with elevated thermostability, elevated stability to acids at p H 2, elevated stability to pepsin and with a broadened active p H range, and to an isolated nucleic acid sequence coding for a synthetic phytase and to the use of the phytase in an animal feed for reducing the phosphate content in the slurry and to animal feed additives and animal feeds comprising the synthetic phytase.Type: ApplicationFiled: April 18, 2012Publication date: February 13, 2014Applicant: BASF SEInventors: Stefan Haefner, Annegret Welzel, Robert Thummer
-
Publication number: 20140047571Abstract: The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella, and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: October 11, 2013Publication date: February 13, 2014Applicant: Novozymes A/SInventors: Carsten Sjoeholm, Soeren Flensted Lassen, Lars Kobberoee Skov, Leonardo De Maria
-
Patent number: 8647848Abstract: The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphingolipids or compositions.Type: GrantFiled: May 22, 2009Date of Patent: February 11, 2014Assignee: Evonik Goldschmidt GmbHInventors: Frank Hollmann, Oliver Thum, Christoph Toelle, Angelo Provinzano, Cornelis Gerrit Nijs Korevaar
-
Patent number: 8647854Abstract: The present invention relates to a metagenome-derived alkaline phosphatase, and more particularly to a novel, metagenome-derived alkaline phosphatase screened using a artificial genetic circuit that detects phenolic compounds, and a preparation method thereof. A novel alkaline phosphatase according to the present invention has high activity of dephosphorylating DNA and can be inactivated rapidly by simple heat treatment. Thus, it can be used for a dephosphorylation reaction so that genetic manipulations, including genetic cloning, become efficient. In addition, it can be actively expressed in recombinant microorganisms, and thus can be used in various assays, including enzyme immunoassay.Type: GrantFiled: June 8, 2010Date of Patent: February 11, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Seung Goo Lee, Su Lim Choi, Eugene Rha, Jae Jun Song